Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.66 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11747973 | 0.98 | ALDH1A1 (0.64) | ALDH1A1KDM4ESLC16A3CA2CYP2D6 | |
| SCHEMBL11793871 | 0.91 | ALDH1A1 (0.57) | ALDH1A1KDM4ESLC16A3CA2CYP2D6 | |
| SCHEMBL31367874 | 0.87 | CYP2D6 (0.59) | ALDH1A1KDM4ESLC16A3CA2CYP2D6 | |
| SCHEMBL1287537 | 0.87 | ALDH1A1 (0.66) | ALDH1A1KDM4ESLC16A3CA2CYP2D6 | |
| SCHEMBL335319 | 0.87 | KDM4E (0.66) | ALDH1A1KDM4ECA2HPGDCA12 | |
| SCHEMBL29527237 | 0.87 | KDM4E (0.66) | ALDH1A1KDM4ECA2HPGDCA12 | |
| Hydrochloric Acid SCHEMBL11498190 | 0.85 | KDM4E (0.64) | ALDH1A1KDM4ECA2HPGDCA12 | |
| SCHEMBL9251599 | 0.85 | CYP2D6 (0.58) | ALDH1A1KDM4ESLC16A3CA2CYP2D6 | |
| SCHEMBL4450673 | 0.85 | KDM4E (0.67) | ALDH1A1KDM4ESLC16A3CA2CYP2D6 | |
| Methylene Chloride SCHEMBL28849518 | 0.83 | LMNA (0.62) | ALDH1A1KDM4ECA2HPGDCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103130705-B | Benzo five-membered unsaturated heterocycle compound or its pharmaceutical salts and preparation method thereof, pharmaceutical composition and application thereof | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2016-04-20 | — | — | CN | claimed |
| EP-2205558-B1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | claimed |
| US-8227504-B2 | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof | SANOFI (FR) | 2012-07-24 | — | — | US | claimed |
| EP-2205558-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | claimed |
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | claimed |
| WO-2009052063-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | claimed |
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HAAG RAINER (DE) | 2004-09-30 | — | — | US | claimed |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2003-07-24 | — | — | US | claimed |
| EP-0031296-B1 | METHOD FOR THE PREPARATION OF BENZAZOLYL COMPOUNDS | CIBA-GEIGY AG (CH) | 1985-08-07 | — | — | EP | claimed |
| EP-0126342-A2 | 3-Alkyl-8-chloro-5,6-dihydrofuro-[3,2-f]-1,2-benzisoxazole-6-carboxylic acids | ABBOTT LABORATORIES (US) | 1984-11-28 | — | — | EP | claimed |
| US-4327209-A | Process for the production of dibenzazolyl compounds | CIBA-GEIGY CORPORATION (US) | 1982-04-27 | — | — | US | claimed |
| EP-0031296-A1 | Method for the preparation of benzazolyl compounds | CIBA-GEIGY AG (CH) | 1981-07-01 | — | — | EP | claimed |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-11-13 | — | — | US | disclosed |
| EP-4431505-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-09-18 | — | — | EP | disclosed |
| CN-118234721-A | Isoindolinone derivative with glutarimide mother nucleus and application thereof | 韩国化学研究院 | 2024-06-21 | — | — | CN | disclosed |
| EP-0031296-A1 | Method for the preparation of benzazolyl compounds | CIBA-GEIGY AG (CH) | 1981-07-01 | — | — | EP | disclosed |
| US-4017483-A | OPTICAL BRIGHTENERS | CIBA-GEIGY CORPORATION (US) | 1977-04-12 | — | — | US | disclosed |
| US-4009994-A | Process and product of optical brightening with quaternized benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1977-03-01 | — | — | US | disclosed |
| US-3940417-A | Quaternised benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | ALDH1A1 198/4885KDM4E 2857/4885SLC16A3 1391/4885 |
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | ALDH1A1 804/4885KDM4E 532/4885SLC16A3 1275/4885 |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | ALDH1A1 198/4885KDM4E 2857/4885SLC16A3 1391/4885 |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | CRBN, IDH1, IDH2 | ALDH1A1 849/4885KDM4E 2129/4885SLC16A3 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.